QLT licenses Atrigel for up to $30 million
This article was originally published in Scrip
QLT has licensed the rights to its Atrigel sustained-release drug technology to Reckitt Benckiser Pharmaceuticals for up to $30 million. QLT USA, the trademark holder of Atrigel, has signed an exclusive licence agreement with Reckitt for the development of the technology, except for certain rights being retained by QLT USA and its prior licensees. QLT USA has received an aggregate up-front payment of $25 million and could receive potential payments of up to $5 million based on the successful development of two Atrigel-formulated products. Reckitt acquired 18 employees from QLT USA and will take over its corporate facility in Fort Collins, Colorado. Bob Butchofsky, QLT president and CEO, said the deal would bring the company's total proceeds from its announced non-core asset transactions to around $240 million. QLT plans to sell a remaining non-core asset, Eligard, a leuprolide acetate for injectable suspension for the palliative treatment of advanced prostate cancer, soon. Eligard is a registered trademark of Sanofi-Aventis.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.